


# ACHIEVING THE END

For the first time, the end of the global AIDS epidemic is within reach. Recent breakthroughs in HIV prevention research have created unprecedented opportunities to curb new HIV infections, save lives and set the world on a path towards eliminating HIV transmission.



## DELIVER

PROVEN TOOLS FOR IMMEDIATE IMPACT

### TREATMENT AS PREVENTION

### VOLUNTARY MEDICAL MALE CIRCUMCISION

DATA

**96%**

reduction in HIV transmission within serodiscordant couples.

CONCEPT


**[PRESENT]**  
Treatment is prevention — preserving health and providing highly-effective prevention.

**[PAST]**  
Treatment preserves health.

TREATMENT GAP

6.6 million people on treatment  
15 million people in need of treatment  
34 million people living with HIV

Goal: 20 M in 14 priority countries



1,535,577 total medical male circumcisions completed as of early 2012

## DEMONSTRATE

AND ROLL OUT NEW HIV PREVENTION OPTIONS

### PRE-EXPOSURE PROPHYLAXIS

### MICROBICIDES

DATA

ON DAILY ORAL TDF/FTC



**42%** reduced risk in men who have sex with men



**75%** reduced risk in heterosexual couples

Effectiveness of PrEP is dependent on adherence.

REGULATORY PATH

July 2012 – US FDA approves TDF/FTC for HIV prevention in HIV-negative adults  
July 2012 (expected) – WHO issues rapid advice on TDF/FTC as PrEP  
2013 and beyond – WHO guidance on use of ARVs; regulatory review in additional countries  
Regulatory review processes needed or are underway in many other countries worldwide.

DEMO PROJECTS

**4**

PrEP demonstration projects planned or underway in MSM and transgender women in the US

**0**

PrEP demonstration projects ongoing in countries outside the US in other populations. At least four are under discussion.

1% TENOFOVIR GEL



**39%**

In 2010 the CAPRISA 004 trial showed 39% reduced risk of HIV infection. In 2011 the VOICE trials showed no effect. Data from the CAPRISA 008 and FACTS 001 trials could be available in 2014.

RECTAL GEL

Safe and acceptable to women and men in the US (MTN 007)

MTN 017, Phase II safety and adherence study of tenofovir gel for rectal use and oral TDF/FTC in MSM and transgender women. Scheduled to start January 2013.

DAPIVIRINE RING

THE RING STUDY (IPM 027)  
ASPIRE (MTN 020)

Phase III safety and efficacy study in 1,850 women. Results expected early 2015.

Phase III safety and efficacy study in 3,476 women. Results expected early 2015.

E  
N  
I  
B  
O  
M  
C

## DEVELOP

LONG-TERM SOLUTIONS NEEDED TO END THE EPIDEMIC

### VACCINES

### CURE

RV144 AND THE P5

**31.2%**

efficacy overall, with higher efficacy at 12 months after immunization.


First vaccine trial to show protection against HIV in humans.

In 2012, follow-up research yielded clues about how the vaccine affected risk of HIV infection.

Pox-Protein Public Private Partnership (P5) formed in 2011 to develop vaccine strategy similar to the one tested in RV144; efficacy trials of this strategy planned in Thailand and South Africa to begin in 2016.

HVTN 505

DOES THE DNA/AD5 VACCINE PROTECT AGAINST HIV?



2,200


Efficacy data are expected by 2014.



ANTIBODY RESEARCH

100'S OF ANTI-HIV ANTIBODIES DISCOVERED SINCE 2009

Scientists have studied blood samples from people living with HIV and identified potent broadly neutralizing antibodies (bNAbs). Studying the structure of these bNAbs and the way that they attach to the virus has provided clues to guide vaccine design. Right now it is not clear how to design a vaccine that generates mature, potent bNAbs. This important work is ongoing.



ONLY 3% OF AIDS RESEARCH FUNDING IS DEVOTED TO AIDS CURE RESEARCH.

End